MEI Pharma Stock News

MEI Pharma Inc (NASDAQ: MEIP) and Kyowa Kirin Co Ltd have announced data from the pivotal Phase 2 TIDAL study of zandelisib as a single agent for follicular lymphoma (FL) patients who received at

State Street Corp increased its holdings in MEI Pharma, Inc. (NASDAQ:MEIP) by 5.7% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 1,871,702 shares of the companys stock after buying an additional 101,586 shares during the period. State Street Corp owned about 1.66% of MEI Pharma worth []

Wall Street analysts expect MEI Pharma, Inc. (NASDAQ:MEIP) to post $7.62 million in sales for the current fiscal quarter, according to Zacks Investment Research. Three analysts have made estimates for MEI Pharmas earnings. The highest sales estimate is $13.40 million and the lowest is $2.20 million. MEI Pharma reported sales of $9.17 million during the []

Squarepoint Ops LLC purchased a new position in shares of MEI Pharma, Inc. (NASDAQ:MEIP) in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 101,993 shares of the companys stock, valued at approximately $291,000. Squarepoint Ops LLC owned 0.09% of MEI Pharma at the end of []

Brokerages expect that MEI Pharma, Inc. (NASDAQ:MEIP) will announce earnings of ($0.19) per share for the current quarter, Zacks reports. Three analysts have made estimates for MEI Pharmas earnings, with the highest EPS estimate coming in at ($0.11) and the lowest estimate coming in at ($0.24). MEI Pharma reported earnings of ($0.22) per share in []

Related Stocks: EPZM , MRUS , ADCT , YMAB , MEIP , NTLA , BCRX , CYTK , VSTM , GERN ,

10 penny stocks to watch this week. The post 10 Top Penny Stocks To Watch With Potential Biotech Catalysts This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.co

MEI Pharma, Inc. (MEIP) delivered earnings and revenue surprises of 0.00% and 34.21%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

MEI Pharma, Inc. (MEIP) CEO Dan Gold on Q4 2021 Results - Earnings Call Transcript

MEI Pharma, Inc. (MEIP) delivered earnings and revenue surprises of 100.00% and 95.18%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

SAN DIEGO , Sept. 2, 2021 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today reported results for its fiscal year

SAN DIEGO, Sept. 2, 2021 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that it will present a com

Mei Pharma (MEIP) doses first patient in phase III study to evaluate zandelisib plus rituximab in follicular lymphoma or marginal zone lymphoma.

SAN DIEGO and TOKYO, Aug. 17, 2021 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa

SAN DIEGO, Aug. 5, 2021 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that Brian Drazba, chief fi